Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.
| Entry into a Material Definitive Agreement. |
As previously reported by Northwest Biotherapeutics, Inc. (the
Company), on March 9, 2017, the Company and the holders (the
Holders) of its 5.00% Convertible Senior Notes due 2017 (the
Notes) entered into a Note Repurchase Agreement (the Repurchase
Agreement). The Notes were issued to an (Indenture), dated August
19, 2014 (the Indenture). On March 17, 2017, the Company executed
a first supplemental indenture to the Indenture, providing that a
default on the Companys payment, performance or other obligations
under the Repurchase Agreement in accordance with its terms also
is also a default under the Indenture and that, if such a default
occurs and is continuing, the principal of all the Notes and
accrued and unpaid interest shall be automatically due and
payable. A copy of the First Supplemental Indenture and the
Repurchase Agreement are attached hereto as Exhibits 10.1 and
10.2, respectively, and are incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description |
| 10.1 |
First Supplemental Indenture, dated March 17, 2017, between Northwest Biotherapeutics, Inc. and The Bank of New York Mellon, as trustee |
| 10.2 |
Repurchase Agreement, dated March 8, 2017, between Northwest Biotherapeutics, Inc. and the holders of 5.00% Convertible Senior Notes due 2017 |
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Recent Trading Information
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) closed its last trading session down -0.010 at 0.226 with 1,227,914 shares trading hands.